Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Moleculin Biotech (MBRX) Return on Equity (2016 - 2025)

Moleculin Biotech has reported Return on Equity over the past 10 years, most recently at 0.04% for Q4 2025.

  • For Q4 2025, Return on Equity rose 6.0% year-over-year to 0.04%; the TTM value through Dec 2025 reached 0.04%, up 6.0%, while the annual FY2025 figure was 0.02%, 1.0% down from the prior year.
  • Return on Equity for Q4 2025 was 0.04% at Moleculin Biotech, up from 0.02% in the prior quarter.
  • Over five years, Return on Equity peaked at 0.04% in Q4 2025 and troughed at 0.05% in Q2 2025.
  • A 5-year average of 0.01% and a median of 0.01% in 2022 define the central range for Return on Equity.
  • Biggest five-year swings in Return on Equity: fell -2bps in 2024 and later rose 6bps in 2025.
  • Year by year, Return on Equity stood at 0.01% in 2021, then tumbled by -94bps to 0.01% in 2022, then plummeted by -81bps to 0.02% in 2023, then rose by 1bps to 0.02% in 2024, then surged by 330bps to 0.04% in 2025.
  • Business Quant data shows Return on Equity for MBRX at 0.04% in Q4 2025, 0.02% in Q3 2025, and 0.05% in Q2 2025.